Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults - PK/ADA

Exclusion Criteria

• 1. Acute illness at study entry (pre-dose on Day 1)
• 2. Fever ≥99.5°F (37.5°C) on day of dosing
• 3. Any drug therapy within 14 days prior to Day 1 (except contraceptives).
• 4. Receipt of immunoglobulin or blood products within 6 months prior to study entry.
• 5. Receipt of any investigational drug therapy within 120 days prior to investigational product dosing or planned to receive any investigational drug therapy within 150 days after investigational product dosing.
• 6. Previous receipt of any marketed or investigational mAb.
• 7. Previous vaccination against RSV.
• 8. History of immunodeficiency or receipt of immunosuppressive medications during the prior year.
• 9. History of asthma.
• 10. History of autoimmune disorder.
• 11. Evidence of any systemic disease on physical examination.
• 12. Evidence of infection with hepatitis A, B, or C virus, syphilis, or human immunodeficiency virus.
• 13. Any clinically significant abnormal laboratory assessments at screening.
• 14. Pregnant or nursing mother.
• 15. Alcohol or drug abuse